Thursday, September 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatoryretatrutidestate pharmacy boardsgray marketcompounding

Pharmacy Times urges state boards to act on illegally sold retatrutide

The commentary targets distribution of an investigational triple agonist that has no FDA approval and no legal compounding pathway.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 4 03:00 ETSource: pharmacytimes.com

The wire

  1. 01A Pharmacy Times piece calls on state boards of pharmacy to take enforcement action against the sale of retatrutide, which is not approved by the FDA.
  2. 02Pharmacists and telehealth operators face growing exposure as gray-market sellers market the unapproved triple agonist directly to consumers.
  3. 03The item is commentary rather than a regulatory action; it is unclear which states, if any, are preparing enforcement steps.

From the source

State Pharmacy Boards Must Step Up Against Illegal Retatrutide

Read at pharmacytimes.com
PeptiPrescribed peptides from $99/moSee all →